Worldwide, major depressive disorder (MDD) affects >300M people, annually causes suicide in 800k people and costs society €1 trillion each year. Many antidepressants are available. Yet, finding the right drug for individual patients remains challenging, as 50% of the patients have not found an effective drug treatment after 1 year. Lately, research including MR imaging has shown promising results. We would like to extend this further, using advanced MRI image analysis including deep learning to create a software tool that can be used in assessment of patients with major depression. With our assessment tool, we aim to reduce the time to selection of an antidepressant that the patient responds to by 75%. This will have major health and economic benefits. The project includes four partners from Norway, The Netherlands and Korea, both universities and small business entities. The project is divided into six work packages: MRI data collection, radiomics analysis, deep learning algorithm development, deep learning validation and prediction model development, cloud system development and project management.
Project leader: Tina Pavlin
Institution: NORDICNEUROLAB AS